Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Dec;82(3):462–468. doi: 10.1111/j.1365-2249.1990.tb05472.x

Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.

J Woo 1, D J Propper 1, A M Macleod 1, A W Thomson 1
PMCID: PMC1535490  PMID: 1702375

Abstract

The effect of administration of cyclosporin A (CyA) or the novel macrolide FK506 was investigated in AO rats given DA blood transfusions. CyA (10 mg/kg, orally) or FK506 (1 mg/kg, intramuscularly) administered for 14 days from the time of transfusion effectively inhibited primary anti-MHC class I alloantibody production. This profound inhibitory effect persisted throughout the 2-month investigation period, with little increase in 'secondary' alloantibody production following a challenge injection 28 days after drug withdrawal. Flow cytometric analysis revealed no significant differences in the absolute numbers of W3/25+ (CD4+), OX-8+ (CD8+) or OX-12+ (B lymphocytes), in either the spleen or peripheral blood of transfused compared with normal, untreated animals. However, a small but significant increase in the numbers of splenocytes expressing the activation marker OX-40 (activated CD4+ cells) was observed in transfused animals. Either CyA or FK506 significantly reduced the number of cells expressing OX-39 (interleukin-2 receptors) and OX-40. Treatment of transfused animals with CyA, but not FK506 for 14 days resulted in minor, transient reduction in peripheral blood OX-19+ and W3/25+ cells, while 'sparing' the OX-8+ cells; these changes were not observed in spleens. In contrast, the absolute spleen cell numbers of OX-19+, W3/25+ and OX-8+ cells were significantly reduced in transfused animals given 14 days of FK506 treatment, while the corresponding blood cells were unaffected. Induction of splenic lymphoproliferative responses by the T cell mitogen concanavalin A remained normal in animals receiving transfusion alone or with CyA. In contrast, profound inhibition of mitogenic responses was observed in FK506-treated animals and this inhibitory effect declined gradually following drug withdrawal. No non-specific suppressor cell activity was detected in the spleens of rats given transfusion alone or in CyA or FK506-treated transfused animals.

Full text

PDF
462

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collier D. S., Thiru S., Calne R. Kidney transplantation in the dog receiving FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):62–62. [PubMed] [Google Scholar]
  2. Inamura N., Nakahara K., Kino T., Goto T., Aoki H., Yamaguchi I., Kohsaka M., Ochiai T. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation. 1988 Jan;45(1):206–209. doi: 10.1097/00007890-198801000-00042. [DOI] [PubMed] [Google Scholar]
  3. Kay J. E., Moore A. L., Doe S. E., Benzie C. R., Schönbrunner R., Schmid F. X., Halestrap A. P. The mechanism of action of FK 506. Transplant Proc. 1990 Feb;22(1):96–99. [PubMed] [Google Scholar]
  4. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 Sep;40(9):1256–1265. doi: 10.7164/antibiotics.40.1256. [DOI] [PubMed] [Google Scholar]
  5. Marquet R. L., Heystek G. A. Cyclosporin a can abrogate the sensitizing effect of blood transfusion in rats without interfering with its beneficial influence. Transplantation. 1981 May;31(5):396–397. doi: 10.1097/00007890-198105010-00019. [DOI] [PubMed] [Google Scholar]
  6. McIntosh L. C., Morrice L. M., Udagawa Y., Thomson A. W. Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology. 1986 Mar;57(3):359–365. [PMC free article] [PubMed] [Google Scholar]
  7. Ochiai T., Nagata M., Nakajima K., Suzuki T., Sakamoto K., Enomoto K., Gunji Y., Uematsu T., Goto T., Hori S. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation. 1987 Dec;44(6):729–733. doi: 10.1097/00007890-198712000-00001. [DOI] [PubMed] [Google Scholar]
  8. Ochiai T., Nakajima K., Nagata M., Hori S., Asano T., Isono K. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987 Dec;44(6):734–738. doi: 10.1097/00007890-198712000-00002. [DOI] [PubMed] [Google Scholar]
  9. Quigley R. L., Wood K. J., Morris P. J. Mediation of antigen-induced suppression of renal allograft rejection by a CD4 (W3/25+) T cell. Transplantation. 1989 Apr;47(4):684–688. doi: 10.1097/00007890-198904000-00022. [DOI] [PubMed] [Google Scholar]
  10. Quigley R. L., Wood K. J., Morris P. J. Mediation of the induction of immunologic unresponsiveness following antigen pretreatment by a CD4 (W3/25+) T cell appearing transiently in the splenic compartment and subsequently in the TDL. Transplantation. 1989 Apr;47(4):689–696. doi: 10.1097/00007890-198904000-00023. [DOI] [PubMed] [Google Scholar]
  11. Salvatierra O., Jr, Vincenti F., Amend W., Potter D., Iwaki Y., Opelz G., Terasaki P., Duca R., Cochrum K., Hanes D. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg. 1980;192(4):543–552. doi: 10.1097/00000658-198010000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shapiro R., Fung J. J., Jain A. B., Parks P., Todo S., Starzl T. E. The side effects of FK 506 in humans. Transplant Proc. 1990 Feb;22(1):35–36. [PMC free article] [PubMed] [Google Scholar]
  13. Starzl T. E., Todo S., Fung J., Demetris A. J., Venkataramman R., Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989 Oct 28;2(8670):1000–1004. doi: 10.1016/s0140-6736(89)91014-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thomson A. W. FK-506--how much potential? Immunol Today. 1989 Jan;10(1):6–9. doi: 10.1016/0167-5699(89)90057-1. [DOI] [PubMed] [Google Scholar]
  15. Tocci M. J., Matkovich D. A., Collier K. A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J. J., Chin J., Hutchinson N. I. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989 Jul 15;143(2):718–726. [PubMed] [Google Scholar]
  16. Todo S., Fung J. J., Demetris A. J., Jain A., Venkataramanan R., Starzl T. E. Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc. 1990 Feb;22(1):13–16. [PMC free article] [PubMed] [Google Scholar]
  17. Todo S., Ueda Y., Demetris J. A., Imventarza O., Nalesnik M., Venkataramanan R., Makowka L., Starzl T. E. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988 Aug;104(2):239–249. [PMC free article] [PubMed] [Google Scholar]
  18. Webster L. M., Thomson A. W. Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol. 1988 Jan;71(1):149–154. [PMC free article] [PubMed] [Google Scholar]
  19. Woo J., Ross C. S., Milton J. I., Thomson A. W. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol. 1990 Jan;79(1):109–114. doi: 10.1111/j.1365-2249.1990.tb05136.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Woo J., Sewell H. F., Thomson A. W. The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. Scand J Immunol. 1990 Mar;31(3):297–304. doi: 10.1111/j.1365-3083.1990.tb02772.x. [DOI] [PubMed] [Google Scholar]
  21. Woo J., Stephen M., Thomson A. W. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology. 1988 Sep;65(1):153–155. [PMC free article] [PubMed] [Google Scholar]
  22. Yoshimura N., Matsui S., Hamashima T., Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation. 1989 Feb;47(2):356–359. doi: 10.1097/00007890-198902000-00035. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES